Unituxin (dinutuximab)

pCPA File Number: 21540
Negotiation Status:
Under consideration for negotiation
Indication(s):
high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor
Sponsor/Manufacturer:
United Therapeutics
CADTH Project Number:
PC0222-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable